GLPG-0492

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
GLPG-0492
Accession Number
DB12461
Type
Small Molecule
Groups
Investigational
Description

Glpg0492 is under investigation in clinical trial NCT01130818 (First-in-Human Single Ascending Dose of GLPG0492).

Structure
Thumb
Synonyms
Not Available
External IDs
(-)-GLPG-0492 / GLPG0492
Categories
UNII
8O59X1ACZT
CAS number
1215085-92-9
Weight
Average: 389.334
Monoisotopic: 389.098725812
Chemical Formula
C19H14F3N3O3
InChI Key
VAJGULUVTFDTAS-GOSISDBHSA-N
InChI
InChI=1S/C19H14F3N3O3/c1-24-17(28)25(14-8-7-12(10-23)15(9-14)19(20,21)22)16(27)18(24,11-26)13-5-3-2-4-6-13/h2-9,26H,11H2,1H3/t18-/m1/s1
IUPAC Name
4-[(4S)-4-(hydroxymethyl)-3-methyl-2,5-dioxo-4-phenylimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
SMILES
CN1C(=O)N(C(=O)[C@@]1(CO)C1=CC=CC=C1)C1=CC=C(C#N)C(=C1)C(F)(F)F

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the fluid retaining activities of GLPG-0492.Investigational
19-norandrostenedione19-norandrostenedione may increase the fluid retaining activities of GLPG-0492.Experimental, Illicit
5-androstenedione5-androstenedione may increase the fluid retaining activities of GLPG-0492.Experimental, Illicit
AcarboseGLPG-0492 may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcenocoumarolGLPG-0492 may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AlbiglutideGLPG-0492 may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneAlclometasone may increase the fluid retaining activities of GLPG-0492.Approved
AldosteroneAldosterone may increase the fluid retaining activities of GLPG-0492.Experimental, Investigational
AlogliptinGLPG-0492 may increase the hypoglycemic activities of Alogliptin.Approved
AmcinonideAmcinonide may increase the fluid retaining activities of GLPG-0492.Approved
AndrostenedioneAndrostenedione may increase the fluid retaining activities of GLPG-0492.Experimental, Illicit
AnecortaveAnecortave may increase the fluid retaining activities of GLPG-0492.Investigational
anecortave acetateanecortave acetate may increase the fluid retaining activities of GLPG-0492.Investigational
AtamestaneAtamestane may increase the fluid retaining activities of GLPG-0492.Investigational
Beclomethasone dipropionateThe risk or severity of fluid retention can be increased when Beclomethasone dipropionate is combined with GLPG-0492.Approved, Investigational
BetamethasoneBetamethasone may increase the fluid retaining activities of GLPG-0492.Approved, Vet Approved
BromocriptineGLPG-0492 may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BudesonideThe risk or severity of fluid retention can be increased when Budesonide is combined with GLPG-0492.Approved
CanagliflozinGLPG-0492 may increase the hypoglycemic activities of Canagliflozin.Approved
ChlorpropamideGLPG-0492 may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
CiclesonideCiclesonide may increase the fluid retaining activities of GLPG-0492.Approved, Investigational
ClobetasolClobetasol may increase the fluid retaining activities of GLPG-0492.Approved, Investigational
Clobetasol propionateClobetasol propionate may increase the fluid retaining activities of GLPG-0492.Approved
ClobetasoneClobetasone may increase the fluid retaining activities of GLPG-0492.Approved
ClocortoloneClocortolone may increase the fluid retaining activities of GLPG-0492.Approved
ClorindioneGLPG-0492 may increase the anticoagulant activities of Clorindione.Experimental
Conestat alfaGLPG-0492 may increase the thrombogenic activities of Conestat alfa.Approved, Investigational
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the fluid retaining activities of GLPG-0492.Investigational
CorticosteroneCorticosterone may increase the fluid retaining activities of GLPG-0492.Experimental
Cortisone acetateCortisone acetate may increase the fluid retaining activities of GLPG-0492.Approved, Investigational
CyclosporineGLPG-0492 may increase the hepatotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
DapagliflozinGLPG-0492 may increase the hypoglycemic activities of Dapagliflozin.Approved
DeflazacortDeflazacort may increase the fluid retaining activities of GLPG-0492.Approved, Investigational
DesonideDesonide may increase the fluid retaining activities of GLPG-0492.Approved, Investigational
DesoximetasoneDesoximetasone may increase the fluid retaining activities of GLPG-0492.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the fluid retaining activities of GLPG-0492.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the fluid retaining activities of GLPG-0492.Experimental, Vet Approved
DexamethasoneThe risk or severity of fluid retention can be increased when Dexamethasone is combined with GLPG-0492.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the fluid retaining activities of GLPG-0492.Vet Approved
DicoumarolGLPG-0492 may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneDiflorasone may increase the fluid retaining activities of GLPG-0492.Approved
DifluocortoloneDifluocortolone may increase the fluid retaining activities of GLPG-0492.Approved, Investigational, Withdrawn
DifluprednateDifluprednate may increase the fluid retaining activities of GLPG-0492.Approved
DiphenadioneGLPG-0492 may increase the anticoagulant activities of Diphenadione.Experimental
DisopyramideGLPG-0492 may increase the hypoglycemic activities of Disopyramide.Approved
DulaglutideGLPG-0492 may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
EmpagliflozinGLPG-0492 may increase the hypoglycemic activities of Empagliflozin.Approved
EquileninEquilenin may increase the fluid retaining activities of GLPG-0492.Experimental
EquilinEquilin may increase the fluid retaining activities of GLPG-0492.Approved
EstroneEstrone may increase the fluid retaining activities of GLPG-0492.Approved
Estrone sulfateEstrone sulfate may increase the fluid retaining activities of GLPG-0492.Approved
Ethyl biscoumacetateGLPG-0492 may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
ExenatideGLPG-0492 may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FluasteroneFluasterone may increase the fluid retaining activities of GLPG-0492.Investigational
FludrocortisoneFludrocortisone may increase the fluid retaining activities of GLPG-0492.Approved, Investigational
FluindioneGLPG-0492 may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneFlumethasone may increase the fluid retaining activities of GLPG-0492.Approved, Vet Approved
FlunisolideFlunisolide may increase the fluid retaining activities of GLPG-0492.Approved, Investigational
Fluocinolone AcetonideFluocinolone Acetonide may increase the fluid retaining activities of GLPG-0492.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the fluid retaining activities of GLPG-0492.Approved, Investigational
FluocortoloneFluocortolone may increase the fluid retaining activities of GLPG-0492.Approved, Withdrawn
FluorometholoneFluorometholone may increase the fluid retaining activities of GLPG-0492.Approved, Investigational
FluprednideneFluprednidene may increase the fluid retaining activities of GLPG-0492.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the fluid retaining activities of GLPG-0492.Approved
FlurandrenolideFlurandrenolide may increase the fluid retaining activities of GLPG-0492.Approved
FluticasoneFluticasone may increase the fluid retaining activities of GLPG-0492.Approved, Experimental, Investigational
Fluticasone furoateFluticasone furoate may increase the fluid retaining activities of GLPG-0492.Approved
Fluticasone propionateThe risk or severity of fluid retention can be increased when Fluticasone propionate is combined with GLPG-0492.Approved
FormestaneFormestane may increase the fluid retaining activities of GLPG-0492.Approved, Investigational, Withdrawn
GabexateGLPG-0492 may increase the thrombogenic activities of Gabexate.Investigational
GliclazideGLPG-0492 may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideGLPG-0492 may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideGLPG-0492 may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburideGLPG-0492 may increase the hypoglycemic activities of Glyburide.Approved
HalcinonideHalcinonide may increase the fluid retaining activities of GLPG-0492.Approved, Investigational, Withdrawn
HE3286HE3286 may increase the fluid retaining activities of GLPG-0492.Investigational
Human C1-esterase inhibitorGLPG-0492 may increase the thrombogenic activities of Human C1-esterase inhibitor.Approved
HydrocortisoneThe risk or severity of fluid retention can be increased when Hydrocortisone is combined with GLPG-0492.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of fluid retention can be increased when Hydrocortisone acetate is combined with GLPG-0492.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of fluid retention can be increased when Hydrocortisone butyrate is combined with GLPG-0492.Approved, Vet Approved
Insulin AspartGLPG-0492 may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirGLPG-0492 may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineGLPG-0492 may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineGLPG-0492 may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanGLPG-0492 may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproGLPG-0492 may increase the hypoglycemic activities of Insulin Lispro.Approved
IstaroximeIstaroxime may increase the fluid retaining activities of GLPG-0492.Investigational
LiraglutideGLPG-0492 may increase the hypoglycemic activities of Liraglutide.Approved
LoteprednolLoteprednol may increase the fluid retaining activities of GLPG-0492.Approved
ME-609ME-609 may increase the fluid retaining activities of GLPG-0492.Investigational
MecaserminGLPG-0492 may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MedrysoneMedrysone may increase the fluid retaining activities of GLPG-0492.Approved
MelengestrolMelengestrol may increase the fluid retaining activities of GLPG-0492.Vet Approved
MetforminGLPG-0492 may increase the hypoglycemic activities of Metformin.Approved
MethylprednisoloneThe risk or severity of fluid retention can be increased when Methylprednisolone is combined with GLPG-0492.Approved, Vet Approved
MifepristoneGLPG-0492 may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolGLPG-0492 may increase the hypoglycemic activities of Miglitol.Approved
MometasoneMometasone may increase the fluid retaining activities of GLPG-0492.Approved, Vet Approved
NateglinideGLPG-0492 may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022NCX 1022 may increase the fluid retaining activities of GLPG-0492.Investigational
Oleoyl-estroneOleoyl-estrone may increase the fluid retaining activities of GLPG-0492.Investigational
ParamethasoneParamethasone may increase the fluid retaining activities of GLPG-0492.Approved
PentamidineGLPG-0492 may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PhenindioneGLPG-0492 may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonGLPG-0492 may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PioglitazoneGLPG-0492 may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PramlintideGLPG-0492 may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteronePrasterone may increase the fluid retaining activities of GLPG-0492.Approved, Investigational, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the fluid retaining activities of GLPG-0492.Investigational
PrednicarbatePrednicarbate may increase the fluid retaining activities of GLPG-0492.Approved, Investigational
PrednisoloneThe risk or severity of fluid retention can be increased when Prednisolone is combined with GLPG-0492.Approved, Vet Approved
PrednisonePrednisone may increase the fluid retaining activities of GLPG-0492.Approved, Vet Approved
PregnenolonePregnenolone may increase the fluid retaining activities of GLPG-0492.Approved, Experimental, Investigational
QuinineGLPG-0492 may increase the hypoglycemic activities of Quinine.Approved
RepaglinideGLPG-0492 may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RimexoloneRimexolone may increase the fluid retaining activities of GLPG-0492.Approved
RosiglitazoneGLPG-0492 may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SaxagliptinGLPG-0492 may increase the hypoglycemic activities of Saxagliptin.Approved
SitagliptinGLPG-0492 may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SulfadiazineGLPG-0492 may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleGLPG-0492 may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleGLPG-0492 may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SunitinibGLPG-0492 may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TioclomarolGLPG-0492 may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolTixocortol may increase the fluid retaining activities of GLPG-0492.Approved, Withdrawn
TolazamideGLPG-0492 may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideGLPG-0492 may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TriamcinoloneTriamcinolone may increase the fluid retaining activities of GLPG-0492.Approved, Vet Approved
UlobetasolUlobetasol may increase the fluid retaining activities of GLPG-0492.Approved
WarfarinGLPG-0492 may increase the anticoagulant activities of Warfarin.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
59317190
PubChem Substance
347828700
ChemSpider
28661578
ChEMBL
CHEMBL2178100

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
1CompletedTreatmentHealthy Volunteers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00522 mg/mLALOGPS
logP2.48ALOGPS
logP2.71ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)14.44ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area84.64 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity92.93 m3·mol-1ChemAxon
Polarizability35.33 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azolidines
Sub Class
Imidazolidines
Direct Parent
Phenylhydantoins
Alternative Parents
Phenylimidazolidines / Trifluoromethylbenzenes / Alpha amino acids and derivatives / Benzonitriles / N-acyl ureas / Dicarboximides / Nitriles / Azacyclic compounds / Primary alcohols / Organopnictogen compounds
show 5 more
Substituents
3-phenylhydantoin / 5-phenylhydantoin / Phenylimidazolidine / Alpha-amino acid or derivatives / Trifluoromethylbenzene / Benzonitrile / N-acyl urea / Ureide / Monocyclic benzene moiety / Benzenoid
show 22 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 16:29 / Updated on August 02, 2018 06:39